Boston Scientific BSX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.56B+23.1% | $2.89B+3.9% | $2.78B+11.5% | $2.5B+23.4% | $2.02B+9.7% | ||
| $1.39B+1.9% | $1.37B+1.3% | $1.35B+2.7% | $1.32B+1.9% | $1.29B+1.7% | ||
| $308M+3.0% | $299M+0.7% | $297M+3.8% | $286M+3.2% | $277M+4.1% | ||
| $279M+3.7% | $269M+3.1% | $261M-0.4% | $262M-23.8% | $344M-2.0% | ||
| —— | —— | —— | —— | —— | ||
| $169M-42.9% | $296M-25.3% | $396M— | —— | —— | ||
| —— | —— | —— | $66M+6,700% | -$1M-150% | ||
| $4.34B-4.3% | $4.53B-2.0% | $4.63B+8.0% | $4.29B+12.4% | $3.81B+11.0% | ||
| $866M-1.1% | $876M+9.2% | $802M+0.3% | $800M+0.3% | $798M+1.0% | ||
| $1.88B+17.8% | $1.59B-67.6% | $4.92B-15.0% | $5.79B+19.9% | $4.83B+4.1% | ||
| -$2.73B-3.4% | -$2.64B+54.7% | -$5.83B+13.7% | -$6.76B-14.5% | -$5.9B-3.8% | ||
| -$888M-125% | -$395M-13,267% | $3M-97.4% | $114M-76.2% | $478M-73.6% | ||
| $5M-88.6% | $44M+37.5% | $32M— | —— | —— | ||
| —— | —— | —— | —— | -$1.58B-250% | ||
| —— | $319M+5.7% | $301.75M+6.1% | $284.5M+6.5% | $267.25M+6.9% | ||
| —— | $561M-4.1% | $584.75M-3.9% | $608.5M-3.8% | $632.25M-3.6% | ||
| -$17M-194% | $18M+80.0% | $10M+142% | -$24M-41.2% | -$17M-240% | ||
| -$394M-19,600% | -$2M+96.7% | -$60M— | —— | —— | ||
| —— | —— | —— | $158M+250% | -$105M-32.9% | ||
| —— | —— | —— | —— | —— | ||
| $53M-59.8% | $132M-25.8% | $178M+5.3% | $169M+28.0% | $132M+159% | ||
| -$129M-53.6% | -$84M-394% | -$17M+5.6% | -$18M+5.3% | -$19M+17.4% | ||
| $116M-54.3% | $254M+29.6% | $196M-21.9% | $251M-13.7% | $291M+3.9% | ||
| $222M-14.0% | $258M— | —— | —— | —— | ||
| $98M-25.2% | $131M-0.8% | $132M+1.5% | $130M+2.4% | $127M+46.0% | ||
| —— | —— | —— | —— | —— | ||
| $20M+186% | $7M+411% | -$2.25M-50.0% | -$1.5M+86.0% | -$10.75M-975% | ||
| —— | —— | —— | —— | -$5M-103% | ||
| $248M-12.1% | $282M-2.8% | $290M+7.0% | $271M+2.3% | $265M+15.2% | ||
| $771M-51.7% | $1.6B— | —— | —— | —— | ||
| —— | $119M+0.4% | $118.5M+0.4% | $118M+0.4% | $117.5M+0.4% | ||
| $3.48B-5.0% | $3.66B-4.3% | $3.82B+9.7% | $3.49B+15.6% | $3.01B+14.0% | ||
| $3.48B-5.0% | $3.66B-4.3% | $3.82B+9.7% | $3.49B+15.6% | $3.01B+14.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Boston Scientific generate?
- Boston Scientific (BSX) generated $4.3B in operating cash flow over the trailing twelve months.
- What is Boston Scientific's free cash flow?
- After $866.0M of capital expenditures, Boston Scientific's free cash flow was $3.5B over the trailing twelve months, up 15.3% year over year.
- Where does Boston Scientific's cash flow data come from?
- Every line is extracted from Boston Scientific's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
